← Back to listJ&J bets $2.2B on Ollin’s vision loss drugBioPharma DiveDelilah AlvaradoNovember 16, 2026The deal hands J J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.Read original article← Back to list